Blis K12^TM :A PROBIOTIC STRAIN WITH CLINICALLY PROVEN EFFECTIVENESS AGAINST ENT INFECTIONS

Streptococcus salivarius BLIS K12™ is a probiotic strain, part of Precision Probio-Therapy^®b: one specific strain, Streptococcus salivarius BLIS K12™ for one specific action – the production of bacteriocins with antibiotic properties.

Streptococcus salivarius BLIS K12™ is a commensal probiotic strain mainly found in the oral cavity and nasopharynx, but also present in the stomach and jejunum. This strain is particularly interesting due to its ability to produce bacteriocins – peptides with antibiotic properties – specifically salivaricin A2 and salivaricin B. These bacteriocins can inhibit the growth of pathogenic Gram-positive bacteria such as Streptococcus pyogenes, a common cause of tonsillitis⁽¹⁾.

A randomized controlled clinical study was conducted on 121 children over the course of one month, using a dosage of 1 billion CFU*/day of Streptococcus salivarius BLIS K12™. A follow-up assessment was performed one month after supplementation ended.

The results showed that the relative abundance of Streptococcus salivarius BLIS K12™ in the supplemented group increased significantly in both saliva and the nasopharynx after just one month of supplementation.

Arthritis symptoms progressively decreased from day 30 through to day 120.

A second randomized controlled clinical study was conducted on 97 children with recurrent upper respiratory tract infections.

For one month, the children received Streptococcus salivarius BLIS K12™, at a dosage of over 1 billion CFU*.

The results demonstrated the efficacy of Streptococcus salivarius BLIS K12™ in reducing the recurrence of infections.

Additionally, several studies have shown the ability of the Streptococcus salivarius BLIS K12™ strain to:

• Colonize the oral cavity, support oral and dental health, and promote a healthy oral environment ^(2,4);

• Reduce the frequency of ENT infections (pharyngitis and acute otitis media) ^(3,5);

• Enhance systemic immune response (increase in Treg cell frequency, reduction in IL-6 levels, and an increase in IL-8 levels after 24 hours) ⁽⁶⁾.

(1) Zupancic, K. et al, (2017). Probiotics and Antimicrobial Proteins (2017).
(2) Sarlin, S., et al (2021). Pediatric Infectious Disease Journal, 40(5), 394–402 (2021).
(3) Guo, H., et al, Frontiers in Nutrition, 9, 900448 (2022).
(4) Tagg J. R.,et al. Frontiers in Microbiology, 14, 1161155 (2023).
 (5)  Walls, T., et al. Journal of Medical Microbiology, 52(10), 829-833 (2003).
(6)  Laws G. L., et al. Probiotics & Antimicro. Prot. 13, 1521–1529 (2021).
 *CFU : Colony Forming Units
 BLIS K12TM is registered trademark of BLIS Technologies Limited.